News

With so many things happening in the diabetes tech world, it can be hard to keep up. Stay up to date here with the latest diabetes tech news and alerts.

Kevin Turner shares his best advice for successful blood sugar management and making life with type 1 diabetes easier.

Key takeaways:

• The t:slim X2 insulin pump is a small, tubed pump with a color touchscreen.
• Users can control the pump directly from the device or using an iPhone or Android smartphone app.
• The t:slim X2 is part of the Control-IQ+ AID system, which automates insulin delivery in combination with a CGM – the Abbott Freestyle Libre 2 Plus/3 Plus or the Dexcom G6/G7.  

A trial is recruiting adults with type 2 diabetes and diabetic kidney disease to investigate an injection into the kidney that could potentially preserve kidney function. The drug has already shown promising results in a phase 2 study, especially in participants with the highest risk of kidney failure.

Researchers are studying teplizumab (Tzield), an approved medication for individuals with stage 2 type 1 diabetes – when type 1 autoantibodies are present and blood sugar levels are elevated, but not high enough to require insulin. The current trial is testing Tzield in youth with newly diagnosed stage 3 type 1 diabetes to see if it can improve A1C and reduce mealtime insulin needs. 

Preliminary evidence suggests that GLP-1 drugs may help people with diabetes-related peripheral neuropathy. This study will explore whether CagriSema, a new GLP-1 drug under investigation, can lessen pain from peripheral neuropathy. 

Incretin-based medicines like Ozempic have shown promising results in studies for reducing alcohol and substance abuse.

Key takeaways:

• Rybelsus is an oral diabetes drug approved as a first-line treatment for people with type 2 diabetes.
• It uses the same active ingredient as Ozempic (semaglutide), the difference being that Rybelsus is an oral medication taken daily, while Ozempic is a weekly injection.
• In October 2025, Rybelsus was approved by the FDA to reduce the risk of major adverse cardiovascular events in people with type 2 diabetes.​

Key takeaways: 

• The FDA has recently issued warnings to companies offering compounded medications with false or misleading claims that their medications are FDA-approved and equivalent in safety to approved drugs like Ozempic.
• Compounded drugs are created by combining or altering ingredients to customize medications for specific individuals. While compounded drugs are sometimes prescribed by healthcare providers for people who can't afford or access a certain drug, they are not FDA-approved.
• The FDA previously issued an alert to healthcare providers, compound pharmacies, and patients about recent overdoses associated with compounded injectable semaglutide.

Key takeaways

• Obesity affects 1 in 3 women in the U.S., increasing the risk of over 200 associated complications. Yet, insurance coverage for obesity treatments is lacking.
• The EveryBODY Covered campaign seeks to address these gaps by advocating for expanded access to comprehensive obesity care.
• The campaign is focused on lifting up women’s personal stories, sharing educational resources, and advocating for expanded policies around obesity care coverage.

Key takeaways:

• Spoonful of Laughter is back for a second year, and we’re continuing to harness the power of comedy as a tool to educate people about diabetes and push back against stereotypes and stigma.
• We’re releasing dozens of new videos starting on October 10, 2025, that show that diabetes can be both serious – and seriously funny.
• You can get involved in our 2025 Spoonful of Laughter movement by watching and sharing all the videos, or by creating your own.

Key takeaways:

• Comedian Sam Morrison shares how comedy has helped him process living with type 1 diabetes, which he was diagnosed with in 2021.
• While of course diabetes is no joke, Morrison explains that using humor to talk about chronic conditions like diabetes is also a powerful tool for pushing back against stigma and stereotypes.
• Covering all this and more, Sam is currently touring all over the country. Coming up, Morrison is performing two special diabetes stand-up shows on August 29 at the Helium Comedy Club in Portland, Oregon.

Are you feeling angry and fearful about diabetes? There’s a way to channel that negative energy into something productive and motivating.

A new global initiative by Abbott aims to help people without diabetes understand what it’s like to live with the condition – and all the stigma that comes with it. 

Key takeaways:

• A panel discussion highlighted promising advances in diabetes technology and medicine aimed at preventing and managing hypoglycemia.
• Real-world experiences illustrated the challenges that people with diabetes face with severe low blood sugar events.
• Early screening and new therapies can help move toward delaying or preventing the progression of type 1 diabetes.

Key takeaways:

• Guidelines generally define time in range between 70 to 180 mg/dL. Time in tight range (70 to 140 mg/dL) is another way of stating the normal glucose range experienced by people without diabetes.
• Time in tight range may be a helpful metric for certain populations, including young children and pregnant people with type 1 diabetes, though more research is needed.
• Concerns around time in tight range for people with diabetes include increased burnout, more stress, and not having access to the proper tools or care team. However, given new technologies and therapies, more people with diabetes may be able to achieve such levels.

Diabetes apps like Glucose Buddy, eddii, mySugr, ChatCGM, and Happy Bob can be useful tools to monitor and improve blood glucose measures, including time in range.

Key takeaways:

• The free online tool Nightscout helps remotely monitor readings from continuous glucose monitors, along with meals, insulin, and other information.
• Online support is available from volunteers who can help with setup, troubleshooting, and creating reports to spot trends.
• The tool is optimized for do-it-yourself hybrid closed loop systems, but it also works with other CGM devices and insulin pumps.

Key takeaways:

• Continuous glucose monitoring (CGM) devices show blood sugar trends over time.
• Consider some tips on how to raise the issue if your doctor hasn't yet suggested CGM use.
• There's a small but manageable learning curve when starting to use a CGM device and reporting back your results to your doctor's office.